Entero Therapeutics (ENTO) just unveiled an announcement.
Entero Therapeutics, Inc. has announced a strategic shift in their executive team, with Dr. Jack Syage transitioning from Chief Operating Officer to Chief Scientific Officer, while maintaining his role as President. This move, effective immediately, comes without changes to his compensation and signifies a realignment of leadership roles within the company to better leverage Dr. Syage’s expertise.
Learn more about ENTO stock on TipRanks’ Stock Analysis page.
